Acacia Research Corporation — 2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013. The filing also reports unaudited fourth-quarter results. Acacia’s operating subsidiaries acquire, partner around, license, and enforce patent portfolios; revenue depends on license agreements and related litigation outcomes.
Financial results and liquidity
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | $130.6 million | $250.7 million |
| Operating income (loss) | $(82.9) million | $80.4 million |
| Net income (loss) attributable to Acacia | $(56.4) million | $59.5 million |
| Diluted earnings (loss) per share | $(1.18) | $1.21 |
| Cash flow from operating activities | $(3.5) million | $104.6 million |
| Cash, cash equivalents and short-term investments at year-end | $256.7 million | $311.3 million |
| Working capital at year-end | $247.7 million | $302.6 million |
| Total liabilities at year-end | $31.2 million | $50.2 million |
Acacia reported no long-term debt or committed credit lines. Year-end assets were $593.4 million, including $288.4 million of net patents. Revenue concentration was significant: two licensees represented 38% and 16% of 2013 revenue.
Fourth-quarter revenue was $15.1 million versus $66.3 million in Q4 2012; Acacia recorded a net loss attributable to the company of $33.3 million versus net income of $9.8 million. Fourth-quarter operating loss was $31.8 million.
Material changes and unusual items
- Full-year revenue declined 48%, reflecting lower average revenue per agreement and fewer agreements: 120 agreements in 2013 versus 138 in 2012; average revenue per agreement fell to $1.088 million from $1.817 million.
- Management attributed weaker revenue partly to only three trial dates in the first half of 2013, which it believed reduced prospective licensees’ incentive to settle. Revenue-generating programs declined to 53 from 68.
- Patent litigation and licensing expense rose 82% to $39.3 million; patent amortization rose 38% to $53.7 million. The latter included $4.6 million of impairment charges on portfolios Acacia would no longer pursue.
- Operating expenses included a $3.5 million charge for resolving a dispute over legal fees from a prior matter. A $22.0 million income tax benefit reduced the reported net loss; Acacia also recorded a valuation allowance against certain deferred tax assets.
- Operating cash flow turned negative despite $133.5 million of licensee cash receipts. Cash and investments declined by $54.6 million, while Acacia paid $18.6 million in dividends and repurchased $7.9 million of stock.
Outlook, risks and contingencies
As of February 28, 2014, management expected approximately 10 trial dates in 2014 and 10–15 in the first half of 2015, noting that trial dates may correlate with potential revenue events but are not reliable predictors. The company was shifting its patent intake strategy toward fewer, higher-quality portfolios and exploring international opportunities. Management stated available liquidity should cover cash requirements through at least March 2015; it provided no revenue or earnings forecast.
- License revenue is volatile and timing-dependent; in 2013, two licensees accounted for 54% of revenue, and two represented 82% of year-end receivables.
- Patent litigation is costly and uncertain, with potential adverse rulings, sanctions, fee awards, or delays. Legislative, regulatory, USPTO, and court changes—including post-grant challenges and possible cost-shifting rules—could impair enforcement economics.
- Patent portfolios may lose value through invalidity challenges, technological obsolescence, or lower-than-expected licensing proceeds; further impairment charges are possible.
- Ordinary-course claims and counterclaims were not expected by management to materially affect consolidated results, but potential court sanctions or attorneys’ fee awards in enforcement matters could be material.
- The board authorized up to $70 million of share repurchases through May 14, 2014. A fourth quarterly dividend of $0.125 per share was approved for payment in March 2014; future dividends remain discretionary.
The independent auditor issued an unqualified opinion on the financial statements and internal controls; management also concluded disclosure controls and internal control over financial reporting were effective at year-end.
Investor verification priorities
- Review the patent-level and licensee-level drivers of the sharp revenue decline, concentration, and receivable collection.
- Track 2014–2015 trial schedules, litigation spending, settlements, and whether the higher-quality portfolio strategy generates returns.
- Assess liquidity and cash burn against dividends, repurchases, patent acquisitions, and management’s March 2015 liquidity horizon.
- Examine the assumptions underlying patent valuations, the $4.6 million impairment, future amortization, and deferred-tax-asset realizability.
- Verify subsequent dividend and repurchase activity, and monitor potential legal sanctions, fee-shifting developments, and changes to patent enforcement rules.